Showing 1311-1320 of 2094 results for "".
Improving Dermatologic Care and Access for Gender and Sexual Minority Patients
https://practicaldermatology.com/conferences/aad-2021/improving-dermatologic-care-and-access-for-gender-and-sexual-minority-patients/19919/Dermatologists need increased knowledge of health disparities and tools to best meet the needs of sexual and gender minority patients. From increased risk of skin cancer in sexual minority individuals to acne in the transgender population, there are many dermatologic concerns arising for patients, sRobert Grant Steps Down at Alphaeon; Skin Cancer Special Edition
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-robert-grant-steps-down-at-alphaeon-skin-cancer-special-edition/18595/Robert Grant is no longer CEO of lifestyle healthcare company Alphaeon. Mr. Grant founded Alphaeon in 2013 as a wholly owned subsidiary of Strathspey Crown LLC, a private equity firm located in Newport Beach, CA, where he serves as Chairman. Also in this issue, a closer look at skin cancer. May is SDerm Insider: Navigating Office Politics
https://practicaldermatology.com/topics/practice-management/derm-insider-navigating-office-politics/18993/In this edition of Derm Insider, host Neal Bhatia, MD speaks with practice management experts about the complex inner workings of an office environment, as well as the role of physicians in managing precarious situations regarding employees. Offering advice for maneuvering these situations, guests SDupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sActinic Keratosis: Therapy Overview
https://practicaldermatology.com/topics/skin-cancer-photoprotection/actinic-keratosis-therapy-overview/19732/Joel Cohen, MD interviews George Martin, MD about the latest developments in actinic keratosis. Dr. Martin said he is eagerly awaiting regulatory review of tirbanibulin, which showed promising results in clinical trials. The two also discuss practical tips and nuances of using 5FU in practice. *Be sLex Icon: Lexington's Randy Waldman Speaks the Language of Successful Site Planning with Joel L. Cohen
https://practicaldermatology.com/topics/practice-management/lex-icon-lexington-s-randy-waldman-speaks-the-language-of-successful-site-planning-with-joel-l-cohen--ovevisoh/18901/How do you plan a brand new, state-of-the art surgical and clinical space that's accessible yet feels exclusive? Should you rent or buy? How do you balance your time? S. Randolph Waldman, MD answers these questions and more from series host Joel L. Cohen, MD in this edition of Best Practices.Staphylococcus aureus Accessory Gene Regulator Quorum-sensing System Inhibits Keratinocyte Lipid Enzymes and Delays Wound Repair
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/staphylococcus-aureus-accessory-gene-regulator-quorum-sensing-system-inhibits-keratinocyte-lipid-enzymes-and-delays-wound-repair/67354/Therapies aimed at inhibiting agr quorum sensing could be a novel strategy to improve healing outcomes.Coral Reefs Under Siege: Is Sunscreen to Blame?
https://practicaldermatology.com/topics/practice-management/coral-reefs-under-siege-is-sunscreen-to-blame/20543/What the science says about the effects of sunscreens on marine life.It’s A Hit! CSF Takes to Music City
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/its-a-hit-csf-takes-to-music-city/23199/If you weren’t at the meeting in Nashville, here’s what you missed.The Microbiome in Atopic Dermatitis: Where Are We Now?
https://practicaldermatology.com/topics/atopic-dermatitis/the-microbiome-in-atopic-dermatitis-where-are-we-now/23746/It seems increasingly likely that microbes will play a central role in understanding AD and its treatments.